Nesfatin-1 was first identified in 2006 as a potent appetite-regulating molecule. The peptide was named for its first described biological action, which was to reduce the dark-phase food intake and weight gain in rats (Nucleobindin2-Encoded Satiety- and Fat-Influencing protein). Subsequently, additional roles of nesfatin-1 have been described in areas such as energy homeostasis, depression and anxiety, cardiovascular system, sleep and reproduction.
Obesity is a serious issue with the worldwide prevalence of obesity almost tripling between 1975 and 2016 according to the World Health Organization. In addition, the increase of overweight and obese children and adolescents is of concern with the prevalence rising to just over 18% among this age group in 2016. Obesity can lead to health conditions such as heart disease, stroke, type 2 diabetes and some types of cancer. Due to the limitations of lifestyle interventions and bariatric surgery for obesity, there is an urgent need for drug treatments. Several peptide drug candidates are currently undergoing development for the treatment of obesity.
This month's highlights include news about more rigid and stable peptides for oral administration, a new input in the fight against COVID-19, a boost for cancer immunotherapy and a novel antiviral peptide for nasopharyngeal cancer.
Marketing Stefan Andlauer, EMBA Director Science & Relationship Marketing stefan.andlauer@bachem.com phone +41 58 595 2107 Marketing Dr. Mirko Lotz Group Leader Science Marketing phone +41 58 595 2760
JOIN OUR WEBINAR! On the 7th of July 2020 we will hold the webinar "Cost-efficient and green manufacturing of peptides thanks to Molecular Hiving technologyTM". Registration and more information can be found here
TECHNICAL LIBRARY
Contact Us
Americas: Bachem Americas, Inc. Toll Free (USA and Canada): +1 888 422 2436 or Tel: +1 310 539 4171 sales.us@bachem.com
